Evoke Pharma Inc. (NASDAQ:EVOK) traded down 15.8% during trading on Wednesday . The stock traded as low as $2.06 and last traded at $2.08, with a volume of 2,012,837 shares traded. The stock had previously closed at $2.47.

Several equities research analysts recently commented on the stock. Northland Securities downgraded shares of Evoke Pharma from an “outperform” rating to a “market perform” rating in a research report on Monday. Zacks Investment Research upgraded shares of Evoke Pharma from a “hold” rating to a “buy” rating and set a $5.50 target price on the stock in a research report on Tuesday, May 3rd. Brean Capital reiterated a “buy” rating on shares of Evoke Pharma in a research report on Wednesday, April 6th. Feltl & Co. downgraded shares of Evoke Pharma from a “strong-buy” rating to a “sell” rating in a research report on Monday. Finally, Rodman & Renshaw reiterated a “buy” rating and set a $27.00 target price on shares of Evoke Pharma in a research report on Monday, July 11th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and three have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $13.34.

The company’s market capitalization is $13.47 million. The firm’s 50 day moving average is $6.38 and its 200-day moving average is $4.77.

Evoke Pharma (NASDAQ:EVOK) last posted its quarterly earnings data on Wednesday, May 11th. The specialty pharmaceutical company reported ($0.45) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.41) by $0.04. Equities research analysts expect that Evoke Pharma Inc. will post ($1.43) earnings per share for the current fiscal year.

In other Evoke Pharma news, major shareholder Parters Vii L. P. Domain sold 344,120 shares of the company’s stock in a transaction that occurred on Thursday, May 26th. The stock was sold at an average price of $4.70, for a total value of $1,617,364.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Parters Vii L. P. Domain sold 5,095 shares of the company’s stock in a transaction that occurred on Wednesday, April 27th. The stock was sold at an average price of $5.07, for a total value of $25,831.65. The disclosure for this sale can be found here.

Evoke Pharma, Inc is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.